Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Houston Methodist Hospital

Houston Methodist Hospital

Houston Methodist Hospital is a hospital and research facility located in Houston, Texas.

COVID-19 Response

Houston Methodist has set up a coronavirus resource center and has mobilized its RNA research group to identify possible preventative measures and treatments for SARS-CoV-2, the virus which causes the disease COVID-19.

COVID-19 Vaccine Research Partnership

Houston Methodist researchers are partnering with GeneOne Life Science Inc. to develop an RNA vaccine against COVID-19, the novel coronavirus that has caused a global pandemic. Houston Methodist developed an RNA therapeutics research program to design, manufacture and test clinical-grade RNA. GeneOne, based in Seoul, South Korea, established its Texas-based manufacturing subsidiary VGXI to build expertise in generating pre-clinical through Current Good Manufacturing Practice (cGMP)-grade DNA plasmids for vaccines, gene therapies and viral vector production. VGXI, GeneOne’s fully owned subsidiary located in The Woodlands, Texas, has a pre-existing exclusive license with Houston Methodist to develop large-batch RNA manufacturing capacity. Together, the group will generate and test an RNA vaccine against COVID-19.

The Houston Methodist RNA therapeutics research program is led by John Cooke, MD, PhD, Joseph C. “Rusty” Walter and Carole Walter Looke Presidential Distinguished Chair in Cardiovascular Disease Research and professor of Cardiovascular Sciences, and Roman Sukhovershin, MD, PhD, scientific director and assistant research professor of Cardiovascular Sciences. The program designs and generates RNA constructs for the scientific and medical communities in the Texas Medical Center in Houston and across the world. In addition to manufacturing non-GMP and cGMP RNA, scientists in Houston Methodist’s RNA therapeutics research program develop technologies to improve the stability and enhance the delivery of RNA products. They also have the facilities to support testing of RNA products in pre-clinical models, as well as a first-in-man clinical trials unit.

The RNA therapeutics research program at Houston Methodist began as a core group for the Progenitor Cell Biology Consortium of the National Heart, Lung, and Blood Institute and is now also supported by the Cancer Prevention Research Institute of Texas to further the development of cutting-edge RNA technologies for cancer. Funding from GeneOne has permitted the program to expand into vaccines.

Timeline

Patents

Further Resources

Title
Author
Link
Type
Date

Research Core Facilities | Houston Methodist

Web

News

Title
Author
Date
Publisher
Description
Lauren Hirsch and Kellen Browning | NYT
July 24, 2021
@bsindia
Some companies said the recent spike in cases had not yet affected their return-to-office planning. Facebook still intends to reopen at 50 percent capacity by early September
Lauren Hirsch and Kellen Browning
July 23, 2021
www.nytimes.com
A wave of the contagious Delta variant is causing companies to reconsider when they will require employees to return, and what health requirements should be in place when they do.
Beth Mole
June 23, 2021
Ars Technica
Nurse who led the fight reportedly has a new job treating people inside their homes.
Molly Hennessy-Fiske, Emily Baumgaertner
June 23, 2021
Los Angeles Times
Houston hospital fires staff for refusing coronavirus vaccine, sparking anti-vax protests
Molly Hennessy-Fiske, Emily Baumgaertner
June 23, 2021
Los Angeles Times
Houston hospital fires staff for refusing coronavirus vaccine, sparking anti-vax protests
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.